

**Table S4.** Factors associated with long-term toxicity-free survival identified by multivariate analysis (myocardial infarction, stroke, and somatropin treatment)

Factor	Types of long-term toxicity					
	Myocardial infarction		Stroke		Somatropin treatment	
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Age (yr)						
≤ 20	-		Ref		Ref	
> 20 and ≤ 47	-		4.40 (0.55–35.2)	0.200	0.03 (0.00–0.23)	< 0.001
> 47	-		16.9 (2.18–130)	0.007	NA	> 0.900
Sex						
Male	-		-		-	
Female	-		-		-	
Subtype						
Lymphoid leukemia (C91)	-		-		Ref	
Myeloid leukemia (C92)	-		-		0.72 (0.21–2.43)	0.600
Others (C93–C95)	-		-		3.18 (0.92–11.0)	0.067
Insurance						
Medicaid	-		-		-	
Medicare	-		-		-	
CCI						
0–2	-		-		-	
3	-		-		-	
≥ 4	-		-		-	
TBI						
Yes vs. No	-		-		-	
CTx						
Bu/Flu or Bu/Flu containing CTx	-		Ref		Ref	
Bu/Cy or Bu/Cy containing CTx	-		0.59 (0.13–2.61)	0.500	0.25 (0.03–2.04)	0.200
Cy or Cy containing CTx	-		2.04 (0.77–5.44)	0.200	0.37 (0.04–3.15)	0.400
Cy/Flu or Cy/Flu containing CTx	-		NA		1.25 (0.15–10.3)	0.800
AraC or AraC containing CTx	-		2.42 (0.53–11.1)	0.258	2.42 (0.71–8.22)	0.200
Flu or Flu containing Ctx	-		1.69 (0.49–5.89)	0.400	2.13 (0.40–11.4)	0.400
Other	-		10.6 (2.39–47.4)	0.002	7.01 (0.82–59.6)	0.075
ATG						
Administered	-		-		-	

TBI, total body irradiation; CCI, Charlson Comorbidity Index; Bu, busulfan; Flu, fludarabine; Cy, cyclophosphamide; CTx, chemotherapy, AraC, cytarabine; ATG, anti-thymocyte globulin; OS, overall survival; HR, hazard ratio; CI, confidence interval; NA, not available.